Trial Profile
A phase II, open-label, randomised controlled trial of icotinib with and without metronomic oral vinorelbine as first-line therapy in patients with EGFR mutation-positive advanced nonsquamous non–small-cell lung cancer.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Icotinib (Primary) ; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Aug 2017 New trial record